Peptides for Men: What the Evidence Actually Shows

Why Men Are the Target Market

Women researching peptides run into a problem: almost nothing was studied in them. Men have the opposite problem, and it is easier to miss.

Men are the target market. The overwhelming majority of peptide marketing — recovery, muscle, “optimization,” longevity — is aimed at men, sold through male-dominated channels, and validated by other men in forums. That volume gets mistaken for evidence. It isn't. A compound can have ten thousand enthusiastic user reports and zero completed human trials, and for several of the most popular peptides on the market, that is exactly the situation.

The second problem is behavioral. Men self-source at much higher rates, consult clinicians at lower rates, and are more likely to stack multiple compounds at once. That combination is how a manageable risk becomes an unmanageable one.

Peptide, Defined — and What Isn't One

A peptide is a short chain of amino acids, generally under 50 residues. Insulin is one. So is semaglutide. So is hCG, roughly speaking, and so is the vial of unlabeled powder someone is selling as a research chemical.

MK-677 is not a peptide. It gets sold, discussed, and stacked as one constantly. It is a small molecule — a spiroindanylpiperidine, around 529 daltons — that mimics ghrelin at the GHS-R1a receptor. It is orally active, which is exactly why it is popular and exactly why the comparison to injectable peptides is misleading. More on its safety record below, because it is worse than most people selling it will tell you.

Similarly, SARMs are not peptides. Neither is anastrozole, clomiphene, or enclomiphene. Clinics bundle these together under “peptide therapy” because it sounds cutting-edge and vaguely natural. It is a marketing category, not a pharmacological one.

The Three Tiers of Evidence

Not everything sold as a “peptide” carries the same weight of evidence. It helps to sort them into three tiers, because almost everything driving male peptide search volume sits in the third one.

Almost everything driving male peptide search volume sits in the third row.

The Regulatory Situation in 2026

Anything written on this before spring 2026 is out of date, and anything written before this week is about to be.

In September 2023, the FDA placed 19 widely used peptides into Category 2 of its Section 503A bulk drug substances list — the designation for substances raising significant safety concerns — which blocked compounding pharmacies from preparing them. Demand did not disappear. It moved to unregulated sellers, and the research-chemical market expanded to absorb it.

In February 2026, HHS announced an intent to reverse course. That was policy signaling, not law. The formal action came April 15, 2026, when the FDA removed 12 peptides from Category 2, effective April 23: BPC-157, LL-37, DiHexa, DSIP (emideltide), Epitalon, injectable GHK-Cu, KPV, PEG-MGF, Melanotan II, MOTS-c, Semax, and TB-500.[1]

That removal did not authorize compounding. It lifted a prohibition designation. Legal compounding requires a substance to be added to the 503A bulks list, which requires advisory committee review, FDA acceptance, and formal rulemaking.

The Pharmacy Compounding Advisory Committee is meeting July 23–24, 2026 (docket FDA-2025-N-6895) to review seven of the twelve: BPC-157, KPV, TB-500, and MOTS-c on day one; DSIP, Semax, and Epitalon on day two. A second review covering five more, including injectable GHK-Cu, is scheduled before the end of February 2027.[2]

Three details that most coverage is leaving out:

• •The FDA's own scientists recommended against all seven. The agency's briefing documents, applying the four-factor framework under 21 CFR 216.23(c), propose the same conclusion for each compound: do not add it to the list. Career staff and current political leadership are not aligned here.
• •The docket drew roughly 1,860 comments, which is enormous for a compounding review, and the committee's composition has itself drawn scrutiny over industry ties.
• •A yes vote changes nothing immediately. The recommendation is advisory. Even full acceptance triggers notice-and-comment rulemaking that typically runs twelve months or longer. In the previous round of peptide reviews, the committee voted against inclusion in the large majority of cases.

The Male-Specific Risk Almost Nobody Mentions: IGF-1 and the Prostate

Every growth hormone secretagogue works the same basic way. It raises GH, which raises IGF-1. Elevated IGF-1 is the point — it is what drives the body composition and recovery effects people are paying for.

It is also associated with prostate cancer, and the evidence is better than most clinics acknowledge.

In UK Biobank, following 199,698 men, higher circulating IGF-1 was associated with prostate cancer diagnosis (HR 1.09 per 5 nmol/L increment, 95% CI 1.05–1.12) and with prostate cancer mortality (HR 1.15, 95% CI 1.02–1.29). Critically, Mendelian randomization analysis using genetic instruments supported a causal role rather than mere correlation (cis-MR odds ratio 1.34 per 5 nmol/L, 95% CI 1.07–1.68).[4] Earlier meta-analysis found an odds ratio of 1.47 for men in the high versus low IGF-1 range.[5]

The honest counterweight: a 2026 systematic review noted meaningful heterogeneity across studies and did not find a clean dose-response gradient, and some data suggest high IGF-1 associates more with lower-grade disease.[6] This is not a settled question, and the absolute risk increments are modest.

But here is the part that matters practically. Nobody has run a trial of chronic GH secretagogue use in healthy middle-aged men with prostate cancer as an endpoint. The exposure most men are contemplating — years of deliberately elevated IGF-1, starting in their forties — is precisely the exposure that has never been studied. “No evidence of harm” and “no evidence” are different statements, and the peptide industry consistently reports the second as the first.

The Thing Men Find Out Too Late: Fertility

This deserves its own section because the sequencing is brutal and avoidable.

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis. Intratesticular testosterone — normally 50 to 100 times serum levels and a prerequisite for sperm production — collapses. One study of eugonadal men starting TRT found intratesticular testosterone dropped by 94%.[7] Azoospermia occurs in roughly 65% of men on testosterone replacement.

Most men on TRT are not told this clearly, or are told it is reversible and stop listening. It usually is reversible, but recovery takes months and is not guaranteed, particularly after prolonged high-dose use.

This is where the genuinely useful male-specific peptide sits. Low-dose hCG co-administered with testosterone maintains intratesticular testosterone and preserves spermatogenesis. In the trial that established this, men receiving low-dose hCG subcutaneously every other day alongside TRT maintained intratesticular testosterone rather than losing it,[7] and follow-up work showed spermatogenesis preserved at one year.[8] For men who have already suppressed, hCG combined with FSH restored sperm concentration in about 74% of a cohort of 77 men with prior testosterone use — and, notably, staying on testosterone during the recovery protocol did not impede it.[10]

hCG is an FDA-approved drug. Enclomiphene and clomiphene work through a different mechanism, stimulating the HPG axis rather than replacing it downstream.[9] Gonadorelin has become a common substitute in clinics, largely for supply and compounding reasons rather than superior evidence.[15]

Compound by Compound

GLP-1 and dual agonists

The strongest evidence in this article, and men are underdiagnosed and undertreated for obesity relative to women despite comparable prevalence. For the fuller picture, see our guide to peptides for weight loss.

Male-relevant considerations:

• •Lean mass. Rapid weight loss costs skeletal muscle regardless of sex, and men typically have more to lose in absolute terms. Resistance training and adequate protein intake are not optional add-ons; they determine whether the weight you lose is the weight you wanted to lose. A DEXA body-composition scan separates fat loss from lean-mass loss.
• •Testosterone. Significant weight loss frequently raises endogenous testosterone in men with obesity-related hypogonadism, sometimes enough to change the calculus on whether TRT was needed at all. Worth re-measuring after meaningful loss rather than assuming the baseline number was destiny.
• •Thyroid history. Boxed warning regarding thyroid C-cell tumors; contraindicated with personal or family history of medullary thyroid carcinoma or MEN2.
• •Sleep apnea. Common, underdiagnosed in men, and improves substantially with weight loss. Worth screening.

Bremelanotide (PT-141)

Approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women. The approved label states it is not indicated for use in men. Any male use is off-label.[3]

That said, the male data is not nothing. Phase 1 and 2A work using penile rigidity monitoring showed responses versus placebo, and Phase 2B trials in men with diabetes-related erectile dysfunction showed improvement in IIEF scores.[14] It acts centrally on melanocortin receptors rather than on vascular smooth muscle, which is why it draws interest for men who do not respond to PDE5 inhibitors — a group estimated at 30–40% of users. Development for a male indication was never pursued to approval. See our companion guide to peptides for libido.

Nausea is the dominant side effect, affecting roughly 40% of participants in the Phase 3 female trials. It raises blood pressure transiently and is not recommended in uncontrolled hypertension or known cardiovascular disease. Combining it with PDE5 inhibitors compounds the blood pressure effect, and stacking on top of nitrates is dangerous. Priapism risk goes up with combination use.

Compounded nasal spray versions circulating through wellness clinics are not the FDA-approved product and have no equivalent quality or evidence basis.

Tesamorelin (Egrifta)

A GHRH analog with genuine FDA approval, studied largely in men, for HIV-associated lipodystrophy. It works for that. Extrapolating from that indication to general body recomposition in a healthy 45-year-old is not supported by comparable data, and it raises IGF-1, which loops back to the prostate discussion above. More detail in our profile of tesamorelin.

Sermorelin, ipamorelin, CJC-1295

The GH secretagogue category, and the backbone of most “anti-aging” clinic protocols for men. Sermorelin has the longest clinical history. The mechanism is real — these do increase GH pulsatility.

What is missing is outcome data. There are no large, long-term randomized trials in healthy men showing that raising GH and IGF-1 into the upper range improves anything that matters — mortality, function, injury rates — as opposed to improving surrogate markers and how you look in a mirror. Known effects of sustained GH elevation include fluid retention, carpal tunnel symptoms, joint pain, insulin resistance, and, in excess, cardiac remodeling. See our overview of peptides for anti-aging for how these are used and monitored.

MK-677 (ibutamoren)

Not a peptide, and the safety record is the worst in this article.

In the Adunsky hip fracture trial in elderly patients, congestive heart failure occurred in 6.5% of the MK-677 group versus 1.7% on placebo, and the trial was terminated early because of it.[11] The FDA has cited exactly this signal, describing significant safety risks from potential congestive heart failure. In a separate two-year study, subjects had a sustained rise in fasting glucose and a decrease in insulin sensitivity that persisted for the full trial duration.[12] Merck never advanced it to Phase III.

It is not approved for human use anywhere. It appears on the World Anti-Doping Agency Prohibited List and the Department of Defense Prohibited Dietary Supplement Ingredients List — relevant if you compete, serve, or hold a job with testing.[13] The FDA has issued warning letters to companies selling it. A 2025 analysis found it among the most frequently detected compounds in seized illegal sports-performance products, frequently misrepresented.

The community has drifted to half the trial dose, which tells you something about tolerability but nothing about long-term safety.

BPC-157, TB-500, Epitalon, MOTS-c

The compounds driving most male peptide search traffic. Being direct: there are no completed human randomized controlled trials for BPC-157 or TB-500. Full thymosin beta-4 has some trial history, including a Phase 2 dry eye program that missed its endpoints. The tendon and tissue-repair claims come from rodent studies, many with methodological weaknesses and none establishing a human dose. Our guide to peptides for healing covers what the evidence does and does not support.

They also cannot legally be compounded right now, meaning nearly everyone taking them is injecting a research chemical of unverified identity and sterility. That risk exists independent of whether the molecule itself does anything.

We are not providing dosing or vendor information for these. There is no evidence-based dose to give.

Follistatin, myostatin inhibitors, IGF-1 LR3

Skip these. Myostatin pathway manipulation has failed repeatedly in clinical development for muscle-wasting conditions, and the gray-market products claiming to do it are unverifiable. IGF-1 LR3 bypasses the body's regulatory feedback entirely, which is the whole selling point and also the whole problem — see the prostate section. If muscle is the goal, our peptides for muscle growth guide covers the evidence-based landscape.

Melanotan II

Sold to men for tanning and, secondarily, for erectile effects. It is a nonselective melanocortin agonist associated with nausea, blood pressure changes, spontaneous erections and priapism, and changes to existing moles with new pigmented lesions. Case reports describe melanoma in users. The cosmetic upside is not worth the dermatologic downside.

Safety Checklist Specific to Men

• •Prostate. Baseline PSA and a family history discussion before anything that raises IGF-1. Repeat monitoring if you proceed.
• •Fertility. If children are possibly in your future, address this before starting TRT, not after.
• •Hematocrit. TRT raises red cell mass; peptide clinics that bundle TRT often monitor this poorly. Erythrocytosis is a thrombotic risk.
• •Glucose. GH secretagogues and MK-677 impair insulin sensitivity. If you are prediabetic, this matters more than the marketing suggests.
• •Sleep apnea. GH and testosterone can worsen it. Snoring plus daytime fatigue plus a new protocol deserves a sleep study.
• •Cardiac. MK-677 has a documented CHF signal. Bremelanotide is contraindicated in cardiovascular disease.
• •Drug testing. WADA, NCAA, DoD, and many employers test. Several compounds in this article will produce a positive result, and “it was labeled a supplement” is not a defense.
• •Stacking. Most reported harm comes from combinations, not single agents. Every added compound multiplies the interaction surface and makes attribution impossible when something goes wrong.

Questions Worth Asking Any Clinic

1. Is this FDA-approved for anything? If not, is it currently on the 503A bulks list?
2. Where is it compounded, and can I see a third-party certificate of analysis?
3. What human randomized trials exist — not rodent studies, not case series?
4. What baseline labs are you running, including PSA, hematocrit, fasting glucose, and IGF-1?
5. What result would make you stop treatment?
6. If I want to father children, how does this change the plan?
7. Do you have a financial relationship with the dispensing pharmacy?

A clinic that answers all seven directly is operating differently from one that redirects to before-and-after photos. Our physician-supervised peptide therapy clinic in Miami is built around exactly this kind of monitoring.

The Short Version

The peptides with real evidence in men are mostly the boring, approved ones: GLP-1 medications for weight, hCG for fertility preservation, tesamorelin for its narrow indication. The compounds generating the most excitement have the least human data, cannot currently be compounded legally, and are being purchased from sellers with no quality accountability.

The specific risk profile that goes underdiscussed for men is the IGF-1 axis, because the mechanism that produces the results people want is the same mechanism with a prostate cancer association behind it. That trade-off should be made deliberately with a clinician, not absorbed by default from a marketing page. Start at the peptide therapy hub for evidence-graded profiles of individual compounds.